Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

TDP2 Antikörper

GMP Grade TDP2 Reaktivität: Human WB Wirt: Maus Monoclonal 42c unconjugated
Produktnummer ABIN2704362
  • Target Alle TDP2 Antikörper anzeigen
    TDP2 (tyrosyl-DNA phosphodiesterase 2 (TDP2))
    Reaktivität
    • 52
    • 31
    • 8
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 52
    • 15
    Maus
    Klonalität
    • 54
    • 13
    Monoklonal
    Konjugat
    • 28
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser TDP2 Antikörper ist unkonjugiert
    Applikation
    • 51
    • 30
    • 28
    • 25
    • 23
    • 13
    • 13
    • 11
    • 7
    • 6
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB)
    Produktmerkmale
    EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5'- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease. Emerging data suggest that EAPII is a multi-functional protein: it repairs enzyme (topoisomerase)-mediated DNA damage by removing phosphotyrosine from DNA adducts, involves in multiple signal transduction pathways such as TNF-TNFR, TGFβ and MAPK, and responsive to immune defense including inflammatory response, viral infection and DNA toxins (chemo or radiation therapy). EAPII predominantly localizes to the nucleus, but based on pathological conditions it also localizes in both cytoplasm and nucleus.
    Aufreinigung
    Purified
    Reinheit
    >95 %
    Güteklasse
    GMP Grade
    Immunogen
    Recombinant full length protein
    Klon
    42c
    Isotyp
    IgG2b kappa
    Top Product
    Discover our top product TDP2 Primärantikörper
  • Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.5 mg/mL
    Buffer
    PBS pH 7.2, 0.1 % (w/v) BSA, 0.09 % (w/v) sodium azide
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C
  • Target
    TDP2 (tyrosyl-DNA phosphodiesterase 2 (TDP2))
    Andere Bezeichnung
    EAPII (TDP2 Produkte)
    Synonyme
    AD022 antikoerper, EAP2 antikoerper, EAPII antikoerper, TTRAP antikoerper, dJ30M3.3 antikoerper, hTDP2 antikoerper, ad022 antikoerper, eap2 antikoerper, ttrap antikoerper, D13Ertd656e antikoerper, Ttrap antikoerper, tdp2 antikoerper, ttrapl antikoerper, tyrosyl-DNA phosphodiesterase 2 antikoerper, tyrosyl-DNA phosphodiesterase 2 S homeolog antikoerper, tyrosyl-DNA phosphodiesterase 2b antikoerper, TDP2 antikoerper, tdp2.S antikoerper, Tdp2 antikoerper, tdp2b antikoerper
    Hintergrund
    EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5'- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease. Emerging data suggest that EAPII is a multi-functional protein: it repairs enzyme (topoisomerase)-mediated DNA damage by removing phosphotyrosine from DNA adducts, involves in multiple signal transduction pathways such as TNF-TNFR, TGFβ and MAPK, and responsive to immune defense including inflammatory response, viral infection and DNA toxins (chemo or radiation therapy). EAPII predominantly localizes to the nucleus, but based on pathological conditions it also localizes in both cytoplasm and nucleus.
    NCBI Accession
    NM_016614
    UniProt
    O95551
Sie sind hier:
Kundenservice